Currently, there are 3.72M common shares owned by the public and among those 3.70M shares have been available to trade.
The company’s stock has a 5-day price change of 38.16% and 56.72% over the past three months. BLRX shares are trading -38.67% year to date (YTD), with the 12-month market performance down to -81.75% lower. It has a 12-month low price of $2.30 and touched a high of $35.60 over the same period. BLRX has an average intraday trading volume of 27.47K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 50.71%, 64.18%, and -52.75% respectively.
Institutional ownership of Bioline Rx Ltd ADR (NASDAQ: BLRX) shares accounts for 0.25% of the company’s 3.72M shares outstanding.
It has a market capitalization of $19.53M and a beta (3y monthly) value of 1.13. The earnings-per-share (ttm) stands at -$2.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.75% over the week and 8.03% over the month.
Earnings per share for the fiscal year are expected to increase by 96.78%, and -31.90% over the next financial year. EPS should grow at an annualized rate of 64.43% over the next five years, compared to 46.38% over the past 5-year period.
Looking at the support for the BLRX, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on May 18, 2017, with the firm’s price target at $1-$3. Rodman & Renshaw coverage for the Bioline Rx Ltd ADR (BLRX) stock in a research note released on February 13, 2017 offered a Buy rating with a price target of $3. Maxim Group was of a view on August 12, 2016 that the stock is Hold, while Maxim Group gave the stock Buy rating on August 17, 2015, issuing a price target of $8- $4. ROTH Capital on their part issued Buy rating on July 27, 2015.
